Bone Marrow vs Adipose Tissue as ACT Source: How ALIV Chooses | ALIV

One of the most common clinical questions in ALIV's pre-ACT consultations is: which source will be used for my procedure — bone marrow or adipose tissue? This is an important question, not because one is universally superior, but because the two sources have meaningfully different cell populations and growth factor profiles that make each more appropriate for different clinical applications. ALIV's clinical team makes this selection based on the specific condition and the therapeutic goals of the individual patient, not from a standard protocol applied to all.

Bone Marrow: The Haematopoietic and Stromal Rich Source

Bone marrow aspirate contains two primary therapeutically relevant populations: haematopoietic cells (red blood cell, white blood cell, and platelet progenitors) and mesenchymal stromal cells (MSCs) alongside a rich plasma environment. The MSC population in bone marrow — while numerically smaller than in adipose tissue — has been extensively studied and is associated with potent immunomodulatory paracrine activity and high HGF content. Bone marrow is the preferred source for applications where systemic immunomodulation is the primary goal (inflammatory arthritis, IBD, autoimmune conditions) and where hepatic regenerative support is relevant (liver conditions, HGF-rich preparation).

The harvest procedure — aspiration from the posterior iliac crest under local anaesthesia — involves a brief, well-tolerated (under appropriate anaesthesia) aspiration of 30–60ml. Recovery is typically one to two days of harvest site soreness. The total volume of therapeutically relevant cells per millilitre is lower in bone marrow than in adipose tissue, which is why relatively precise patient preparation (nutritional status, hydration) significantly affects the quality of the aspirate.

Adipose Tissue: The MSC-Rich Source

Adipose tissue contains a substantially higher density of MSCs per gram of tissue than bone marrow — estimates suggest 100–500 times the MSC yield per unit volume. Adipose-derived MSCs (ADSCs) have a slightly different paracrine profile from bone marrow MSCs, with particularly high expression of neurotrophic factors (BDNF, NGF, VEGF) making them the preferred source for neurological applications (Parkinson's, Alzheimer's, SCI, stroke). The harvest involves a small lipoaspiration from the abdomen or flank under local anaesthesia — less procedure-site discomfort than bone marrow aspiration for most patients. ADSCs are also significantly easier to expand (grow in culture) if cell expansion is part of an advanced protocol, though ALIV's standard protocols use fresh same-day preparations rather than expanded cells.

Can ALIV use both sources in the same procedure?

In some advanced protocols, both bone marrow and adipose tissue are harvested in the same session — the preparations are either combined or used for different administration routes targeting different clinical goals simultaneously. This approach is more resource-intensive and involves two harvest sites but allows the complementary growth factor profiles of both sources to be delivered together. It is considered for complex multi-system conditions where the therapeutic goals benefit from both the immunomodulatory profile of bone marrow and the neurotrophic profile of adipose-derived preparations. This decision is made at the pre-ACT consultation.

Does the patient's weight or body composition affect the adipose harvest?

Very lean patients with minimal subcutaneous fat may yield lower adipose volumes from a small lipoaspiration — in these patients, bone marrow may be the preferred or sole source. For patients with adequate subcutaneous adipose tissue, the adipose harvest is technically straightforward regardless of overall body weight. The clinical team assesses adipose availability at the pre-ACT consultation and selects the most appropriate source accordingly.

Is the bone marrow harvest painful?

Under adequate local anaesthesia, most patients experience pressure sensation during the aspiration rather than sharp pain. The periosteal (bone surface) anaesthesia is the most important component — once this is established, the aspiration itself is usually well-tolerated. Post-procedure soreness at the iliac crest site for one to three days is expected. Patients who are very anxious about the procedure can request mild procedural sedation, arranged in advance with the ALIV clinical team.